Osmotic release of bioactive VEGF from biodegradable elastomer monoliths is the same in vivo as in vitro

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 588-597

  Chapanian, Rafi ^a   Tse, Man Y ^a   Pang, Stephen C ^a   Amsden, Brian G ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Biodegradable polymer; Controlled release; Degradable elastomer; In vitro in vivo correlation; Osmosis; Osmotic pressure release; Protein delivery; Vascular endothelial growth factor

Indexed keywords

1,3 TRIMETHYLENE CARBONATE; DEXTRO,LEVO LACTIDE; ELASTOMER; POLYCAPROLACTONE; RECOMBINANT VASCULOTROPIN; SERUM ALBUMIN; TREHALOSE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TOLERABILITY; ERYTHROCYTE; FEASIBILITY STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OSMOTIC PRESSURE; PROTEIN CROSS LINKING; RADIOACTIVITY; RAT;

EID: 84455179009     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22782     Document Type: Article

References (32)

1. Libby P. 2002. Inflammation in atherosclerosis. Nature 420(6917):868-874.
2. Heart Disease and Stroke Statistics-2006 Update. 2006. American Heart Association: Dallas, Texas.
3. Kleiman NS, Patel NC, Allen KB, Simons M, Yla-Herttuala S, Griffin E, Dzau VJ. 2003. Evolving revascularization approaches for myocardial ischemia. Am J Cardiol 92(9B):9N-17N.
4. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, Sellke FW. 2002. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiov Sur 124(1):28-34.
5. Cao YH, Hong A, Schulten H, Post MJ. 2005. Update on therapeutic neovascularization. Cardiovasc Res 65(3):639.
6. van de Weert M, van Steenbergen MJ, Cleland JL, Heller J, Hennink WE, Crommelin DJA. 2002. Semisolid, self-catalyzed poly(ortho ester)s as controlled release systems: Protein release and protein stability issues. J Pharm Sci 91(4):1065-1074.
7. Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A. 2001. Development of poly-(d, l-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release 72(1-3):13-24.
8. Golub JS, Kim YT, Duvall CL, Bellamkonda RV, Gupta D, Lin AS, Weiss D, Taylor WR, Guldberg RE. 2010. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol-Heart C 298(6):H1959-H1965.
9. Sheridan M, Shea L, Peters MC, Mooney DJ. 2000. Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J Control Release 64:91-102.
10. van de Weert M, Hennink WE, Jiskoot W. 2000. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17(10):1159-1167.
11. Gopferich A, Gref R, Minamitake Y, Shieh L, Alonso MJ, Tabata Y, Langer R. 1994. Drug delivery from bioerodible polymers: Systemic and intravenous administration. In Formulation and delivery of proteins and peptides; Cleland JL, Langer R, Eds. Washington: ACS.
12. 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J Pharm Pharmacol 54:897-905.
13. Ekholm M, Hietanen J, Lindqvist C, Rautavuori J, Santavirta S, Suuronen R. 1999. Histological study of tissue reactions to e-caprolactone-lactide copolymer in paste form. Biomaterials 20:1257-1262.
14. Kavanagh CA, Gorelova TA, Selezneva, II, Rochev YA, Dawson KA, Gallagher WM, Gorelov AV, Keenan AK. 2005. Poly(N-isopropy acrylamide) copolymer films as vehicles for the sustained delivery of proteins to vascular endothelial cells. J Biomed Materials Res Part A 72A(1):25-35.
15. Lee KY, Peters MC, Mooney DJ. 2003. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J Control Release 87(1-3):49-56.
16. Elcin YM, Dixit V, Gitnick G. 2001. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: Implications for tissue engineering and wound healing. Artificial Organs 25(7):558-565.
17. Gu F, Amsden B, Neufeld R. 2004. Sustained delivery of vascular endothelial growth factor with alginate beads. J Control Release 96(3):463-472.
18. Peters MC, Isenberg BC, Rowley JA, Mooney DJ. 1998. Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomat Sci-Polym E 9(12):1267-1278.
19. Jay SM, Saltzman WM. 2009. Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking. J Control Release 134(1):26-34.
20. Amsden B. 2003. A model for osmotic pressure driven release from cylindrical rubbery polymer matrices. J Control Release 93:249-258.
21. Amsden BG, Cheng YL, Goosen MFA. 1994. A mechanistic study of the release of osmotic agents from polymeric monoliths. J Control Release 30(1):45-56.
22. Gu F, Neufeld R, Amsden B. 2007. Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device. J Control Release 117:80-89.
23. Chapanian R, Tse MY, Pang SC, Amsden BG. 2009. The role of oxidation and enzymatic hydrolysis on the in vivo degradation of trimethylene carbonate based photocrosslinkable elastomers. Biomaterials 30(3):295-306.
24. Chapanian R, Tse MY, Pang SC, Amsden BG. 2010. Long term in vivo degradation and tissue response to photo-cross-linked elastomers prepared from star-shaped prepolymers of poly(epsilon-caprolactone-co-d, l-lactide). J Biomed Materials Res Part A 92A(3):830-842.
25. Timbart L, Tse MY, Pang SC, Amsden BG. 2010. Tissue response to, and degradation rate of, photocrosslinked trimethylene carbonate-based elastomers following intramuscular transplantation. Materials 3:1156-1171.
26. Chapanian R, Amsden B. 2010. Combined and sequential delivery of bioactive VEGF165 and HGF from poly(trimethylene carbonate) based photo-cross-linked elastomers. J Control Release 143:53-63.
27. Amsden B. 2007. Review of osmotic pressure driven release of proteins from monolithic devices. J Pharm Pharmaceut Sci 10(2):129-143.
28. Post MJ, Simons M. 2001. Gene therapy versus protein-based therapy: A matter of pharmacokinetics. Drug Discovery Today 6(15):769-770.
29. Larsen C, Larsen SW, Jensen H, Yaghmur A, Ostergaard J. 2009. Role of in vitro release models in formulation development and quality control of parenteral depots. Expert Opin Drug Deliv 6(12):1283-1295.
30. De la Riva B, Nowak C, Sanchez E, Hernandez A, Schulz-Siegmund M, Pec MK, Delgado A, Evora C. 2009. VEGF-controlled release within a bone defect from alginate/chitosan/PLA-H scaffolds. Eur J Pharm Biopharm 73(1):50-58.
31. Ehrbar M, Zeisberger SM, Raeber GP, Hubbell JA, Schnell C, Zisch AH. 2008. The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 29(11):1720-1729.
32. Wang T, Ameer GA, Sheppard BJ, Langer R. 2002. A tough biodegradable elastomer. Nature Biotechnol 20:602-606.